Zevra Therapeutics, Inc. reported significant financial performance improvements in its latest quarterly filing, with net revenue reaching $36.2 million for the three months ended March 31, 2026, compared to $20.4 million during the same period in 2025. This 77.5% increase was primarily driven by sales of its FDA-approved product MIPLYFFA, which generated $24.6 million in revenue, up from $17.1 million in the prior year. The company also recognized a gain of $43.3 million from the sale of certain assets, contributing to a net income of $37.9 million, a substantial turnaround from a net loss of $3.1 million in the previous year.
The company’s total assets decreased slightly to $278.6 million as of March 31, 2026, from $284.7 million at the end of 2025. Notably, cash and cash equivalents increased to $95.6 million, up from $62.4 million, reflecting improved liquidity. Zevra's stockholders' equity rose to $205.8 million, compared to $154.7 million at the end of the previous fiscal year, indicating a strengthened financial position.
Strategically, Zevra has made significant moves, including the completion of an asset sale to Commave Therapeutics, which resolved ongoing litigation and allowed the company to focus on its core products. The settlement agreement resulted in a total payment of $50 million, with $45 million received in the first quarter of 2026. Additionally, the company is actively pursuing regulatory approval for MIPLYFFA in the European Union, having filed a Marketing Authorization Application with the European Medicines Agency in July 2025.
Operationally, Zevra has maintained a focus on expanding its market presence. The company continues to utilize a single specialty pharmacy provider for the distribution of its products, and it is engaged in an expanded access program for MIPLYFFA in France and select territories outside Europe. As of March 31, 2026, the company reported total receivables of $22.1 million, down from $23.3 million at the end of 2025, reflecting ongoing adjustments in its revenue recognition practices. The company’s employee headcount has also increased, supporting its growth initiatives.
Looking ahead, Zevra anticipates continued growth driven by the commercialization of its products and potential new partnerships. The company is focused on enhancing its research and development pipeline while managing its operational expenses effectively. However, it acknowledges the inherent risks and uncertainties associated with regulatory approvals and market conditions that could impact future performance.
About ZEVRA THERAPEUTICS, INC.
Zevra Therapeutics is a biotech company focused on developing and commercializing therapies for rare diseases. Its portfolio includes approved products like AZSTARYS and OLPRUVA, and late-stage candidates such as MIPLYFFA for Niemann-Pick disease type C. The company leverages proprietary technology, strategic acquisitions, and collaborations to address unmet medical needs in niche markets worldwide. Its business model emphasizes innovation, targeted commercialization, and pipeline expansion in the rare disease space.
About 10-Q Filings
A 10-Q form is an important financial report that public companies in the United States must submit every three months. It gives a clear picture of a company's financial health and recent performance.
Key points about the 10-Q:
- Frequency: Companies file it three times a year, covering the first three quarters. The fourth quarter is covered in a more comprehensive annual report.
-
Content: It includes:
- Financial statements showing the company's current financial position
- Updates from management on the performance and projections of the business
- Information about potential risks the company faces
- Details on how the company is run internally
- Deadline: Must be filed within 40 or 45 days after the quarter ends, depending on the size of the company.
Our Methodology
AssetRoom is committed to providing timely summaries of news from public companies. We use AI to generate these summaries quickly, but they are not reviewed by human experts.
Our method:
- Data Collection: We continuously monitor for new filings (currently limited to US-listed stocks).
- AI-Powered Analysis: Our advanced AI system processes each filing, identifying key information and extracting relevant data.
- Summary Generation: The AI creates a concise, easy-to-understand summary of the filing, highlighting the most important points.
- Publication: The summary is immediately published on our platform, allowing users instant access to the latest information.
- Email users: We distribute round-up emails according to our users preferences, keeping them in the loop with the companies they follow.
Feedback & Corrections
Spot an error or have a suggestion? Contact us.